SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to news regarding an amended agreement to increase its ownership stake in the Tanbreez rare earth project in Greenland. The community is discussing the implications of this deal, particularly its potential impact on the company's valuation and future prospects, with some suggesting a possible US government stake. Investors are also weighing the connection to other rare earth and lithium plays, and assessing the potential for a significant squeeze.

The project was established through the BAGS.FM app which is platform that allows projects to create projects with cause, our project directly generates trading fees and processes them through the BAGS app to directly donate towards the official Dolphin Project - We're the first crypto token to passively provide donations and change to acquatic life and have already raised $8,000 towards providing sactuary for captured dolphins.

Dolphin

Dolphin Crypto is trending as social media buzz points to a potential breakout, with many highlighting the ease of access through Phantom Wallet. The community is closely watching the chart, anticipating a significant move and emphasizing early entry advantages. Momentum and liquidity appear to be building, fueling speculation of a substantial uptrend.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending following news of trial updates and increased volume, leading to a surge past its 52-week high. Community members are actively speculating about a potential buyout and the implications of new partnerships. Discussions also revolve around the company's financial health and future growth prospects in the competitive pharmaceutical landscape.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as community members discuss its potential rally, drawing comparisons to Dogecoin's past success. The recent listing on Robinhood is a key point of discussion, although some note the price hasn't yet reacted as expected. Community members are also excited about the project's utility and broader ecosystem.

Bonk is the first Solana dog coin for the people, by the people with 50% of the total supply airdropped to the Solana community. The Bonk contributors were tired of toxic “Alameda” tokenomics and wanted to make a fun memecoin where everyone gets a fair shot.

BONK

BONK is gaining traction as Solana's leading meme coin, fueled by expanding utility through dApp integrations and exchange listings. The BONK community is actively discussing potential catalysts, including upcoming token burns and growing institutional interest, which could drive the price higher. With Solana's low fees and fast transactions, BONK trading is frictionless, attracting new traders and bolstering community growth.

SanDisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk ($SNDK) is trending as investors discuss the potential of HBF technology and its impact on memory capacity, while some community members express concerns about losses and a possible downturn. The stock's recent price action and potential overbought conditions are also being debated, with analysts adjusting price targets amid the ongoing discussions around AI and memory demand. Recent reports show promise of expanding into new facilities in Japan.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending as investors analyze upcoming earnings, with community discussions focused on the potential impact of travel demand and labor costs on the company's performance. Recent analyst ratings and price target adjustments are also fueling the conversation, alongside mentions of unusual options activity and technical chart patterns. Traders are also weighing the potential effects of Trump-era tariffs on the airline industry.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXPI is gaining attention, partly driven by unusual options activity suggesting potentially bearish sentiment among some traders. Community members are also discussing its exposure to the automotive chip market and potential benefits from the AI sector. Analysts are weighing in with updated ratings and price targets, contributing to the ongoing conversation.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

NMAX is trending as investors discuss unusual options activity and potential upside, with some highlighting LEAPS call options. Community members are sharing perspectives on the stock's overnight dips and potential catalysts, including its relationship to other Trump-related stocks and the broader media landscape. The stock is also being discussed in the context of political events and media budgets.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI is trending following positive Phase 2 clinical trial results for their treatment-resistant depression drug, BPL-003. Community members are actively discussing the potential for a scalable psychedelic therapy and anticipating further data releases. Some investors are drawing comparisons to other Thiel-backed companies like Palantir and expressing excitement about the future of psychedelic medicine.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI

Two medical sector stocks are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list in Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI). 

Hong Kong-headquartered investment management firm Yunqi Capital on Monday announced its opposition to STAAR Surgical Company’s (STAA) proposed sale to Alcon (ALC).Yunqi holds a 5.1% stake in STAAR Surgical Company and has been an investor since 2023. The firm, which claims to be approximately the sixth-largest shareholder of STAAR, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250922086063/en/Yunqi-Capital-5.1-Holder-and-One-of-STAAR-Surgical-Companys-Largest-Shareholders-Announces-Intention-to-Vote-Against-the-Proposed-Sale-to-Alcon">stated</a> that it opposes the acquisition of STAAR on the terms announced in August.Shares of STAAR traded 1% lower in the pre-market session, while <a href="https://stocktwits.com/symbol/ALC">ALC shares</a> traded 1% higher. On Stocktwits, retail sentiment around the <a href="https://stocktwits.com/symbol/STAA">STAA ticker</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_8_12_08_AM_png_c5117e5a01.webp" alt="STAA's Sentiment Meter and Message Volume as of 8:12 a.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>STAA's Sentiment Meter and Message Volume as of 8:12 a.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Yunqi alleged in a letter to other shareholders that it would not necessarily be opposed to a potential merger of the two companies at an appropriate price or on other appropriate terms. “In conclusion, while we are not necessarily opposed to supporting an acquisition of STAAR by a third party, including Alcon, at an appropriate price or on other appropriate terms, we remain open to a range of potential outcomes, including continued ownership of STAAR as an independent company for the foreseeable future,” it said.&nbsp;“Given STAAR’s momentum and bright future, we believe the $28 per share offer price significantly undervalues our company. We are disappointed that STAAR’s Board of Directors has agreed to sell our company to Alcon Inc. at this inadequate valuation and on the terms of the definitive merger agreement dated August 4, 2025,” it added in a letter to other shareholders.Yunqi said that the Staar’s board failed in its responsibility by not running sufficient market checks or thoroughly soliciting potential interest from a range of alternative buyers and potential strategic partners. Yunqi also stated that it disagrees with the Board’s bleak assessment of the macroeconomic climate in China, which it believes contributed to the company’s decision to accept such a low offer price from Alcon.Earlier this month, Broadwood Partners, L.P., and its affiliates also announced their intention to vote against the proposed acquisition. Broadwood is STAAR’s largest shareholder, owning 27.3% of STAAR’s common shares outstanding.STAAR is a manufacturer of phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Alcon <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.alcon.com/news-and-events/press-releases/news-details/2025/Alcon-Agrees-to-Acquire-STAAR-Surgical/default.aspx">said</a> in early August that the companies have entered into a definitive merger agreement under which Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash. The transaction is expected to close in about six to 12 months and represents a total equity value of approximately $1.5 billion, it added.Meanwhile, STAAR announced the expiration of the 45-day “window shop” period on Monday, stating that the company received no competing acquisition proposal despite Broadwood Partners actively exploring alternative buyers over the past few weeks. CEO Stephen Farrell noted that the expiration of the ‘window shop’ period with no competing acquisition proposal reinforces the Board’s conclusion that the Alcon merger maximizes value for STAAR stockholders.“Collectively, the Board and management team understand the market risks, trends, and opportunities better than Broadwood, and Broadwood’s opposition to the transaction is unfounded,” Farrell said. The company also added that if the proposed merger is not approved, stockholders will be exposed to significant value destruction, and urged shareholders to reject Broadwood’s claims.STAA stock is up 12% this year and down approximately 10% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/metsera-stock-surges-pre-market-after-pfizer-confirms-acquisition/chDQNVhR3cy">Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor's Note: The story has been updated with STAAR Surgical Company’s statement.

Global stock market chart and trading board - stock photo

STAAR Surgical’s Shareholder Yunqi Capital Opposes Proposed Merger With Alcon – Here’s Why

Yunqi alleged in a letter to other shareholders that the proposed merger undervalues Staar and announced its intention to vote against the proposed sale. 

Equity

Yunqi alleged in a letter to other shareholders that the proposed merger undervalues Staar and announced its intention to vote against the proposed sale. 


Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.

Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up

ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.

Hologic (HOLX) Soars 7.7%: Is Further Upside Left in the Stock?

Hologic (HOLX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Do Options Traders Know Something About Alcon Stock We Don't?

Investors need to pay close attention to ALC stock based on the movements in the options market lately.

Glaukos Builds Dual Growth Engines Amid Market Headwinds

GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.

Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges

ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.

Compared to Estimates, Alcon (ALC) Q2 Earnings: A Look at Key Metrics

The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Stay Ahead of the Game With Alcon (ALC) Q2 Earnings: Wall Street's Insights on Key Metrics

Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the Surgical and Vision Care segments. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner in 1945 and is headquartered in Geneva, Switzerland.

Alcon Inc. - Registered Shares

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.76	--	--	N/A
Q2 '25	$0.72	$0.76	6.22%	BEAT
Q1 '25	$0.75	$0.73	-3.15%	MISSED
Q4 '24	$0.71	$0.72	1.85%	BEAT
Q3 '24	$0.74	$0.81	9.19%	BEAT

ALC
Alcon Inc. - Registered Shares

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ALC News

ALC Alcon Inc. - Registered Shares